HER-2 NEGATIVE BREAST CANCER
Clinical trials for HER-2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER-2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER-2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo offers hope for Tough-to-Treat breast cancer
Disease control Recruiting nowThis study tests a combination of two drugs, eribulin and anlotinib, in people with HER2-negative advanced breast cancer who have already tried other treatments. The goal is to see if the combination can slow down the cancer and help people live longer. About 52 participants will…
Matched conditions: HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated May 26, 2026 11:12 UTC
-
New drug combo shows promise for Tough-to-Treat breast cancer
Disease control Recruiting nowThis study tests a combination of two drugs, utidelone and bevacizumab, in people with advanced HER-2 negative breast cancer who have already tried at least two other treatments. The goal is to see if the combination can slow or stop the cancer from growing. About 79 women aged 1…
Matched conditions: HER-2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 26, 2026 10:35 UTC